Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290981 | 0.85 | MAPT (0.51) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL3038362 | 0.85 | MAPT (0.51) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL13198307 | 0.84 | TP53 (0.66) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL3049440 | 0.83 | LMNA (0.53) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL13198299 | 0.82 | MAPT (0.51) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL13290974 | 0.82 | LMNA (0.51) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL3045446 | 0.82 | LMNA (0.51) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL31338679 | 0.82 | LMNA (0.53) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL804656 | 0.82 | LMNA (0.51) | LMNAMAPTTP53TSHRRAB9A | |
| SCHEMBL774396 | 0.82 | FLT3 (0.53) | LMNAMAPTTP53TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2012-03-22 | — | — | US | disclosed |
| EP-2218464-A1 | Compounds for non-invasive measurement of aggregates of amyloid peptides | Technische Universität München (DE) | 2010-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | IAPP, APP, HTT | LMNA 1196/4885MAPT 10/4885TP53 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.